Dynorphin A(1-8): stability and implications for in vitro opioid activity

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Dynorphin A(1-8) is an endogenous opioid peptide with complex interactions at opioid receptors.
• Understanding its binding profile and in vitro activity is crucial for elucidating opioid signaling pathways.

Purpose of the Study:

• To investigate the opioid binding profile and in vitro activity of dynorphin A(1-8).
• To assess the impact of metabolism on dynorphin A(1-8)'s receptor interactions and functional effects.

Main Methods:

• Opioid receptor binding assays using guinea-pig brain membranes and C6 glioma cells expressing rat opioid receptors.
• In vitro functional assays including mouse vas deferens and guinea-pig ileum preparations.
• Use of peptidase inhibitors to block dynorphin A(1-8) metabolism.

Main Results:

• Dynorphin A(1-8) exhibited nonselective binding to mu, delta, and kappa opioid receptors, with some preference for delta.
• High metabolism of dynorphin A(1-8) was observed, with [Leu5]enkephalin as a major metabolite.
• In the presence of peptidase inhibitors, dynorphin A(1-8) showed increased affinity for kappa receptors, but still lacked selectivity.
• In vitro agonist effects were mediated by kappa receptors, but metabolism led to delta and mu receptor activation via [Leu5]enkephalin.

Conclusions:

• Dynorphin A(1-8) lacks intrinsic receptor selectivity in binding assays.
• Its in vitro agonist effects are primarily mediated through the kappa opioid receptor.
• Metabolism significantly alters dynorphin A(1-8)'s activity, leading to indirect activation of other opioid receptor subtypes.